Drugs / ASC930
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04883918 | Dec 2023 → Jan 2026 | acute graft versus host disease | ASC Therapeutics | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASC930 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04883918 ↗ |
| Route | Intravenous | “4 intravenous (IV) doses of ASC930” NCT04883918 ↗ |